IDENIX PHARM
Norcod AS engages in the farming, production, operation, distribution, marketing, and sale of farmed cod products in Norway and internationally. The company was incorporated in 2018 and is headquartered in Trondheim, Norway.
IDENIX PHARM (NO9) - Total Assets
Latest total assets as of September 2025: €588.63 Million EUR
Based on the latest financial reports, IDENIX PHARM (NO9) holds total assets worth €588.63 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
IDENIX PHARM - Total Assets Trend (2019–2024)
This chart illustrates how IDENIX PHARM’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
IDENIX PHARM - Asset Composition Analysis
Current Asset Composition (September 2024)
IDENIX PHARM's total assets of €588.63 Million consist of 49.4% current assets and 50.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.9% |
| Accounts Receivable | €32.72 Million | 4.9% |
| Inventory | €277.67 Million | 41.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.00 Million | 0.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how IDENIX PHARM's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IDENIX PHARM's current assets represent 49.4% of total assets in 2024, a decrease from 84.4% in 2019.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2024, down from 23.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 41.2% of total assets.
IDENIX PHARM Competitors by Total Assets
Key competitors of IDENIX PHARM based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Riverview Rubber Estates Bhd
KLSE:2542
|
Malaysia | RM406.55 Million |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥10.49 Billion |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
China | CN¥505.58 Million |
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
China | CN¥3.52 Billion |
|
Luoniushan Co Ltd
SHE:000735
|
China | CN¥10.05 Billion |
|
New Hope Liuhe Co Ltd
SHE:000876
|
China | CN¥116.87 Billion |
|
Yuan Longping High-tech Agriculture Co Ltd
SHE:000998
|
China | CN¥25.48 Billion |
|
Dongrui Food Group Co Ltd
SHE:001201
|
China | CN¥6.21 Billion |
IDENIX PHARM - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - IDENIX PHARM generates 0.59x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - IDENIX PHARM is currently not profitable relative to its asset base.
IDENIX PHARM - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 1.00 | 3.21 |
| Quick Ratio | 0.22 | 0.09 | 0.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-29.45 Million | € 931.00K | € 241.41 Million |
IDENIX PHARM - Advanced Valuation Insights
This section examines the relationship between IDENIX PHARM's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.72 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | €673.98 Million |
| Market Capitalization | $24.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values IDENIX PHARM's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: IDENIX PHARM's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for IDENIX PHARM (2019–2024)
The table below shows the annual total assets of IDENIX PHARM from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | €673.98 Million | -3.00% |
| 2023-09-30 | €694.79 Million | +28.23% |
| 2022-09-30 | €541.85 Million | -2.64% |
| 2021-09-30 | €556.52 Million | +19.86% |
| 2020-09-30 | €464.31 Million | +1165.55% |
| 2019-09-30 | €36.69 Million | -- |